[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mid-rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mid-rectal-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579361","can-neoadjuvant-chemoradiotherapy-be-ommited-in-mid-rectal-cancer-100579361",false,"NCT06823297","Can Neoadjuvant Chemoradiotherapy be Ommited in Mid-rectal Cancer","Can Neoadjuvant Chemoradiotherapy be Omitted in cT2N+ and cT3 Mid-rectal Cancer: A Prospective, Observational Cohort Study","CANO","Inclusion Criteria:\n\n* Pathologically confirmed rectal cancer\n* Rectal cancer within 6-12 cm from anal verge confirmed by sigmoidoscopy or located between the anorectal junction and peritoneal reflection identified by MRI\n* Clinical local staging performed by MRI\n* cT2N+, cT3N0 and cT3N+ tumors\n* Patients without mesorectal fascia involvement assessed by MRI (≤1 mm)\n* Patients without pathological (short axis ≥7 mm) lateral (extramesorectal) lymph nodes on MRI\n* Patients without EMVI on MRI\n\nExclusion Criteria:\n\n* cT4 tumors\n* Stage IV disease\n* Patients with MSI (+) in TME pathology\n* PAtients who received neoadjuvant immunotherapy\n* Emergency surgery\n* Clinical obstruction\n* Previous pelvic radiotherapy\n* Patients treated without a multidisciplinary council decision\n* Inflammatory bowel diseases (Crohn's disease, Ulcerative colitis)\n* Familial adenomatous polyposis (FAP), attenuated FAP, and other polyposis syndromes\n* Hereditary non-polyposis colorectal cancer (Lynch syndrome)\n* Synchronous colon tumors","ALL","18 Years",{"count":20,"type":21},436,"ESTIMATED","5 Years","OBSERVATIONAL","This project aims to compare the oncological and functional outcomes of patients with mid-rectal cancer who have a low risk of local recurrence (without MRF involvement) and who either receive or do not receive neoadjuvant chemoradiotherapy (nCRT).\n\nMain Question:\n\nH0: In mid-rectal cancer patients without MRF involvement (cT2N+ and cT3Nx), there is no difference in 3-year disease-free survival between direct TME and TME after nCRT.\n\nH1: In mid-rectal cancer patients without MRF involvement (cT2N+ and cT3Nx), direct TME is associated with worse 3-year disease-free survival compared to TME after nCRT.\n\nParticipants already taking both interventions as part of their regular medical care for rectal cancer will be recruited in a prospective database for 5 years.",[26,27,28],"Mid-Rectal Cancer","Rectal Cancer Stage II","Rectal Cancer Stage III",[26,30,31],"Radiotherapy","Mesorectal fascia","NOT_YET_RECRUITING","2025-06-23",{"date":35,"type":36},"2025-06-27","ACTUAL",{"date":38,"type":21},"2025-08-01",{"date":40,"type":21},"2035-08-01",{"name":42,"class":43},"Turkish Society of Colon and Rectal Surgery","OTHER",5]